Xilio Therapeutics presents new data across portfolio at SITC

Xilio Therapeutics (XLO) announced new data across its portfolio, including preclinical data highlighting the potential for Xilio’s masked T cell engager platform and programs, as well as Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, and Phase 2 data related to circulating tumor DNA for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4. The data are being presented in multiple presentations at the Society for Immunotherapy of Cancer, SITC, 40th Annual Meeting, taking place from November 5-9, 2025, in National Harbor, Maryland. Key findings: Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index; Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile; Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, show potential for ctDNA as an early predictor for response to treatment with vilastobart in combination with atezolizumab in patients with MSS mCRC